We are contrasting VistaGen Therapeutics Inc. (NASDAQ:VTGN) and Iterum Therapeutics plc (NASDAQ:ITRM) on their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics Inc.	N/A	0.00	24.06M	-0.93	0.00
Iterum Therapeutics plc	N/A	151.78	77.06M	-4.59	0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of VistaGen Therapeutics Inc. and Iterum Therapeutics plc.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics Inc.	0.00%	-608.9%	-267.7%
Iterum Therapeutics plc	0.00%	0%	0%

Liquidity

The Current Ratio of VistaGen Therapeutics Inc. is 3.6 while its Quick Ratio stands at 3.6. The Current Ratio of rival Iterum Therapeutics plc is 14 and its Quick Ratio is has 14. Iterum Therapeutics plc is better equipped to clear short and long-term obligations than VistaGen Therapeutics Inc.

Institutional & Insider Ownership

Institutional investors held 18% of VistaGen Therapeutics Inc. shares and 76.8% of Iterum Therapeutics plc shares. VistaGen Therapeutics Inc.’s share held by insiders are 0.1%. Competitively, Iterum Therapeutics plc has 1.2% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
VistaGen Therapeutics Inc.	-16.18%	-30.91%	-33.33%	-23.49%	-3.39%	-24%
Iterum Therapeutics plc	-1.36%	-11.64%	-16.41%	-47.84%	0%	8.28%

For the past year VistaGen Therapeutics Inc. has -24% weaker performance while Iterum Therapeutics plc has 8.28% stronger performance.

Summary

Iterum Therapeutics plc beats VistaGen Therapeutics Inc. on 5 of the 7 factors.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.